Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-27T22:54:05.389Z Has data issue: false hasContentIssue false
  • English
  • Français

A review of vascular disrupting agents as a concomitant anti-tumour modality with radiation

Published online by Cambridge University Press:  02 May 2013

William Tyler Tran ,
Ahmed El Kaffas ,
Azza Al-Mahrouki ,
Carol Gillies  and
Gregory Jan Czarnota
William Tyler Tran*
Affiliation:
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Ahmed El Kaffas
Affiliation:
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
Azza Al-Mahrouki
Affiliation:
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Carol Gillies
Affiliation:
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada
Gregory Jan Czarnota
Affiliation:
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada
*
Correspondence to: William Tyler Tran, Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, TB95, Toronto, Ontario, Cannada M4N 3M5. Tel: 416 480-6100, ext 1026. E-mail: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Tumour vasculature plays an important role in the development, maintenance and sustainability of a tumour. Endothelial cells which are recruited into the tumour stroma facilitate the formation of essential blood vessels that deliver nutrients and oxygen to tumour cells. A growing body of research is showing that there are synergistic anti-tumour effects when anti-vascular agents are combined with radiation. More recent reports have described favourable radiation response as a function of vascular targeting and blood vessel breakdown, primarily through interactions of radiation with vascular endothelial cells. Vascular disrupting agents are being utilised in several forms that include molecular targeting, biophysical assault and biological interference.

Purpose

In the present review, we examine current advances in anti-vascular agents to enhance tumour response when combined with radiation therapy.

Methods

A comprehensive literature search was conducted on the US National Library of Medicine, National Institutes of Health (PubMed) using the following search keywords: vascular disrupting agents, radiation sensitisation, anti-angiogenic therapy, anti-vascular therapy, radiation therapy.

Conclusion

Current research suggests the applicability of vascular disrupting agents as an effective radiation sensitisation agent. Pre-clinical and clinical trials have been well developed to form the theoretical framework to apply this powerful modality to the treatment of cancer.

Keywords

anti-angiogenesisanti-vascular therapycancer therapiesradiation therapyvascular disrupting agents
Type
Literature Review
Information
Journal of Radiotherapy in Practice , Volume 12 , Issue 3 , September 2013 , pp. 255 - 262
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Fidler, I. Molecular biology of cancer: invasion and metastasis in cancer. In: DeVita V T, Rosenberg S A (eds). Cancer: Principle and Practice of Oncology, 5th edition. New York: Lippincott-Raven, 1997: 135–146.Google Scholar
2.Thomlinson, R H. Radiation and the vascularity of tumours. Br Med Bull 1973; 29 (1): 29–32.CrossRefGoogle ScholarPubMed
3.Wachsberger, P, Burd, R, Dicker, A P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003; 9 (6): 1957–1971.Google ScholarPubMed
4.Bergers, G, Benjamin, L E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3 (6): 401–410.CrossRefGoogle ScholarPubMed
5.Delli Carpini, J, Karam, A K, Montgomery, L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 2010; 13 (1): 43–58.CrossRefGoogle Scholar
6.Li, J, Huang, S, Armstrong, E A, Fowler, J F, Harari, P M. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys 2005; 62 (5): 1477–1485.CrossRefGoogle ScholarPubMed
7.Murata, R, Siemann, D W, Overgaard, J, Horsman, M R. Improved tumour response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 2001; 156: 503–509.CrossRefGoogle Scholar
8.Subramanian, J, Morgensztern, D, Govindan, R. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Lung Cancer 2010; 11 (5): 311–319.CrossRefGoogle ScholarPubMed
9.Denekamp, J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 1984; 23 (4): 217–225.CrossRefGoogle ScholarPubMed
10.Moyal, E. Optimizing antiangiogenic strategies: combining with radiotherapy. Targ. Oncol 2008; 3: 51–56.CrossRefGoogle Scholar
11.Nieder, C, Wiedenmann, N, Andratschke, N, Molls, M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 2006; 32 (5): 348–364.CrossRefGoogle ScholarPubMed
12.Folkman, J, Camphausen, K. What does radiotherapy do to endothelial cells? Science 2001; 293: 227–228.CrossRefGoogle ScholarPubMed
13.Paris, F, Fuks, Z, Kang, A et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001; 293 (5528): 293–297.CrossRefGoogle ScholarPubMed
14.Cines, D B, Pollak, E S, Buck, C A et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91 (10): 3527–3561.Google ScholarPubMed
15.Garcia-Barros, M, Paris, F, Cordon-Cardo, C et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300 (5622): 1155–1159.CrossRefGoogle ScholarPubMed
16.McDonald, D M, Baluk, P. Significance of blood vessel leakiness in cancer. Cancer Res 2002; 62 (18): 5381–5385.Google ScholarPubMed
17.Jain, R. Normalization of tumour vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62.CrossRefGoogle ScholarPubMed
18.Riesterer, O, Honer, M, Jochum, W, Oehler, C, Ametamey, S, Pruschy, M. Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res 2006; 12 (11 Pt 1): 3518–3524.CrossRefGoogle ScholarPubMed
19.Shen, S, Fan, J, Cai, B et al. Vascular endothelial growth factor enhances cancer cell adhesion to microvascular endothelium in vivo. Exp Physiol 2010; 95 (2): 369–379.CrossRefGoogle ScholarPubMed
20.Tozer, G M, Kanthou, C, Lewis, G, Prise, V E, Vojnovic, B, Hill, S A. Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol 2008; 81 (Spec No 1): S12–S20.CrossRefGoogle ScholarPubMed
21.Fuks, Z, Kolesnick, R. Engaging the vascular component of the tumor response. Cancer Cell 2005; 8 (2): 89–91.CrossRefGoogle ScholarPubMed
22.Hinnen, P, Eskens, F A. Vascular disrupting agents in clinical development. Br J Cancer 2007; 96 (8): 1159–1165.CrossRefGoogle ScholarPubMed
23.Nishida, N, Yano, H, Nishida, T, Kamura, T, Kojiro, M. Angiogenesis in cancer. Vasc Health Risk Manag 2006; 2 (3): 213–219.CrossRefGoogle ScholarPubMed
24.Health Canada Sutent. 2012. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2007_sutent_101319-eng.php. Accessed on 1st April 2012.Google Scholar
25.Gutheil, J C, Campbell, T N, Pierce, P R et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6 (8): 3056–3061.Google Scholar
26.Auerbach, W, Auerbach, R. Angiogenesis inhibition: a review. Pharmacol Ther 1994; 63 (3): 265–311.CrossRefGoogle ScholarPubMed
27.Takahashi, N, Haba, A, Matsuno, F, Seon, B K. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001; 61 (21): 7846–7854.Google ScholarPubMed
28.Arora, A S, Scholar, E M. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315 (3): 971–979.CrossRefGoogle ScholarPubMed
29.Kaston, M. Molecular biology of cancer: the cell cycle. In: DeVita V T, Rosenberg S A (eds). Cancer: Principle and Practice of Oncology. New York: Lippincott-Raven, 1997: 121–132..Google Scholar
30.Li, M, Ye, C, Feng, C et al. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res 2002; 8 (11): 3570–3578.Google ScholarPubMed
31.Kamiyama, M, Ichikawa, Y, Ishikawa, T et al. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene Ther 2002; 9 (2): 197–201.CrossRefGoogle ScholarPubMed
32.Gerweck, L E, Vijayappa, S, Kurimasa, A, Ogawa, K, Chen, D J. Tumor cell radiosensitivity is a major determinant of tumor response to radiation. Cancer Res 2006; 66 (17): 8352–8355.CrossRefGoogle Scholar
33.Gupta, V K, Jaskowiak, N T, Beckett, M A et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 2002; 8 (1): 47–54.CrossRefGoogle ScholarPubMed
34.Park, J S, Qiao, L, Su, Z Z et al. Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene 2001; 20 (25): 3266–3280.CrossRefGoogle ScholarPubMed
35.Wilson, W R, Li, A E, Cowan, D S, Siim, B G. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 1998; 42 (4): 905–908.CrossRefGoogle Scholar
36.Tiecher, B A, Dupuis, N, Kusomoto, T et al. Antiangiogenic agents can increase tumour oxygenation response to radiation therapy. Radiat Oncol Investigations 1994; 2 (6): 269–276.CrossRefGoogle Scholar
37.Pajonk, F, Vlashi, E, McBride, W H. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 2010; 28 (4): 639–648.CrossRefGoogle ScholarPubMed
38.Baguley, B C, Wilson, W R. Potential of DMXAA combination therapy for solid tumors. Expert Rev Anticancer Ther 2002; 2 (5): 593–603.CrossRefGoogle ScholarPubMed
39.Gould, S, Westwood, F R, Curwen, J O. Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats. J Natl Cancer Inst 2007; 99 (22): 1724–1728.CrossRefGoogle ScholarPubMed
40.Tran, W T, Iradji, S, Sofroni, E. Microbubble and ultrasound radioenhancement of bladder cancer. Br J Cancer 2012; 107 (3): 469–476.CrossRefGoogle Scholar
41.Czarnota, G J, Karshafian, R, Burns, P N. Tumor radiation response enhancement by acoustical stimulation of the vasculature. Proc Natl Acad Sci U S A 2012; 109 (30): E2033–E2041.CrossRefGoogle ScholarPubMed